论文部分内容阅读
随着新型冠状病毒肺炎（简称新冠肺炎）疫情的蔓延，部分精神障碍患者感染2019新型冠状病毒（2019-nCoV），以及新冠肺炎患者在疾病的发展和治疗中继发严重的精神症状，均影响了新冠肺炎的系统治疗，因此需要积极治疗新冠肺炎的同时维持或开始使用精神药物进行治疗，以控制精神症状。由于新冠肺炎患者的躯体基础状况较差，因此对精神药物的耐受性变差，精神药物和新冠肺炎治疗药物联合应用存在一定的相互作用风险。本文中汇总了现有的数据和防治指南，对新冠肺炎患者使用精神药物的耐受性情况、精神药物与其他药物的相互作用以及在特殊人群中使用的注意事项进行详细介绍，希望能为一线医生提供参考。“,”With the spread of COVID-19, some patients with psychiatric disorders have been infected, and their psychiatric symptoms could be fluctuated the pneumonia illness. Besides, a variety of psychiatric symptoms could also be induced by COVID-19 and antiviral drugs-related side effects (e.g., interferon), which might lead to the poorer outcomes of patients and should be treated. Considering the poor physical conditions due to the COVID-19 in pneumonia patients, the tolerability and safety issues of the psychotropic drugs and the potential interactions between psychotropic drugs and antiviral drugs are important clinical challenges. With the systematical review of the up-to-date clinical data and treatment guidelines, this article provides a detailed introduction of the tolerability of psychotropic drugs in patients with COVID-19, the interactions between psychotropic drugs and other kinds of drugs and the precautions for psychotropic drugs use in special populations.